| Primary |
| Glycogen Storage Disease Type Ii |
68.0% |
| Product Used For Unknown Indication |
16.6% |
| Premedication |
4.4% |
| Drug Use For Unknown Indication |
1.8% |
| Immunomodulatory Therapy |
1.3% |
| Cardiomyopathy |
0.8% |
| Bronchitis |
0.6% |
| Depression |
0.6% |
| Gastrooesophageal Reflux Disease |
0.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.6% |
| Stomatitis |
0.6% |
| Immunosuppression |
0.6% |
| Disease Progression |
0.6% |
| Anaemia |
0.5% |
| Gastrointestinal Disorder |
0.5% |
| Hypersensitivity |
0.5% |
| Constipation |
0.4% |
| Bronchial Hyperreactivity |
0.3% |
| Hypertrophic Cardiomyopathy |
0.3% |
| Osteoporosis |
0.3% |
|
| Respiratory Failure |
15.4% |
| Death |
13.3% |
| Vomiting |
9.7% |
| Urticaria |
6.1% |
| Respiratory Disorder |
5.7% |
| Wheezing |
5.5% |
| Tachycardia |
5.0% |
| Pyrexia |
4.9% |
| Respiratory Distress |
4.1% |
| Pneumonia |
3.7% |
| Rash |
3.6% |
| Sepsis |
3.1% |
| Respiratory Tract Infection |
3.0% |
| Therapeutic Response Decreased |
2.8% |
| Urinary Tract Infection |
2.7% |
| Tachypnoea |
2.6% |
| Cardiac Failure |
2.5% |
| Viral Infection |
2.2% |
| Infusion Related Reaction |
2.1% |
| Muscular Weakness |
2.1% |
|
| Secondary |
| Glycogen Storage Disease Type Ii |
54.9% |
| Product Used For Unknown Indication |
17.3% |
| Premedication |
6.3% |
| Disease Progression |
3.6% |
| Bronchitis |
2.6% |
| Gastrointestinal Disorder |
2.1% |
| Hypersensitivity |
1.9% |
| Colitis Ulcerative |
1.7% |
| Diarrhoea |
1.5% |
| Pain |
1.3% |
| Rhinitis Allergic |
1.3% |
| Hypertension |
1.0% |
| Insomnia |
0.9% |
| Pneumothorax |
0.9% |
| Anaemia |
0.5% |
| Drug Use For Unknown Indication |
0.5% |
| Wheezing |
0.5% |
| Anxiety |
0.4% |
| Gastrooesophageal Reflux Disease |
0.4% |
| Malnutrition |
0.4% |
|
| Urticaria |
12.0% |
| Type Iii Immune Complex Mediated Reaction |
8.9% |
| Viral Infection |
8.9% |
| Pyrexia |
8.2% |
| Wheezing |
7.6% |
| Pain |
6.3% |
| Respiratory Failure |
6.3% |
| Drug Ineffective |
5.1% |
| Subdural Haematoma |
5.1% |
| Hypertrophic Cardiomyopathy |
3.8% |
| Skin Discolouration |
3.8% |
| Weight Decreased |
3.8% |
| Anaphylactoid Reaction |
3.2% |
| Tachypnoea |
3.2% |
| Nervous System Disorder |
2.5% |
| Supraventricular Tachycardia |
2.5% |
| Vomiting |
2.5% |
| Weaning Failure |
2.5% |
| Hypotonia |
1.9% |
| Non-cardiac Chest Pain |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
68.5% |
| Glycogen Storage Disease Type Ii |
12.2% |
| Premedication |
8.8% |
| Procedural Pain |
3.3% |
| Cardiomegaly |
2.2% |
| Drug Use For Unknown Indication |
1.7% |
| Fabry's Disease |
1.7% |
| Hypokalaemia |
1.1% |
| Heart Disease Congenital |
0.6% |
|
| Liver Function Test Abnormal |
27.3% |
| Alanine Aminotransferase Increased |
13.6% |
| Tracheitis |
13.6% |
| Blood Creatine Phosphokinase Increased |
9.1% |
| Diarrhoea |
9.1% |
| Serum Sickness |
9.1% |
| Chest X-ray Abnormal |
4.5% |
| Headache |
4.5% |
| Pain |
4.5% |
| Respiratory Syncytial Virus Bronchiolitis |
4.5% |
|
